Sukus, thanks for the comment. You’re right that the Maryland–Virginia corridor is emerging as a major biotech center, and the comparison to South San Francisco does make sense. SSF grew because Genentech anchored the region and the entire ecosystem clustered around it. On the East Coast, the drivers are different but just as strong: FDA White Oak, NIH, NCI, Johns Hopkins, AstraZeneca’s expanding Maryland footprint, and Merck’s West Point complex all sit within roughly a two-hour radius. That proximity naturally concentrates research, manufacturing, and clinical activity into a very efficient biotech ecosystem.
One piece most people overlook is how deeply the federal government has invested in dendritic-cell immunotherapy in this same corridor. Moffitt Cancer Center alone has received over $100 million in combined NIH/NCI and Department of Defense funding for dendritic-cell biology and DC1/alpha-DC1 vaccine programs. That research includes the same alpha-DC1 maturation science that Northwest Biotherapeutics later in-licensed for the DCVax platform. This federal support spans NIH R01 grants focused on dendritic-cell dysfunction, multiple HER2-DC1 breast cancer vaccine trials supported by NIH and DoD, and a recent $22.4 million DoD award for dendritic-cell therapy in leptomeningeal disease.
So yes, the Maryland–Virginia corridor is absolutely becoming a premier hub, but with a unique profile: it’s shaped not just by biotech expansion, but by a tight geographic cluster of regulators, research institutions, major manufacturers, and federally funded immunotherapy programs, including the very dendritic-cell IP that NWBO built its platform on, a combination you don’t see anywhere else in the country.
Bullish
AI
Market Data 
Markets 
